4.2 Article

Deferasirox chelation therapy in patients with transfusion-dependent MDS: a real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata

期刊

EUROPEAN JOURNAL OF HAEMATOLOGY
卷 95, 期 1, 页码 52-56

出版社

WILEY-BLACKWELL
DOI: 10.1111/ejh.12476

关键词

iron chelation; deferasirox; myelodysplastic syndromes; safety; efficacy; erythroid response

资金

  1. Regione Lazio: 'sindromi mielodisplastiche dell'adulto nell'area di Roma e del Lazio: epidemiologia caratteristiche diagnostiche e clinico-terapeutiche, analisi dei costi mediante un registro onco-ematologico regionale'
  2. Novartis Pharmaceuticals Italy

向作者/读者索取更多资源

Deferasirox (DFX) is an orally administered iron chelator approved for use in patients with transfusion-dependent iron overload due to myelodysplastic syndromes (MDS). The safety and efficacy of DFX has been explored in clinical trial settings, but there is little data on unselected patients with MDS. The aim of this study was to retrospectively evaluate the safety, compliance, efficacy and effect on haematopoiesis of DFX in a large real-world' MDS population. One hundred and eighteen patients with transfusion-dependent MDS were treated with DFX across 11 centres in Italy. Serum ferritin levels, haematological response, dosing, adverse events and transfusion dependence were recorded at baseline, 3, 6, 12 and 24months following initiation of treatment. DFX reduced mean serum ferritin levels from 1790 to 1140ng/mL (P<0.001), with 7.1% of patients achieving transfusion independence. Significant haematological improvement was seen in erythroid (17.6%), platelet (5.9%) and neutrophil counts (7.1%). Adverse events were reported in 47.5% of patients, including gastrointestinal and renal toxicity. Regression analysis showed that higher starting doses of DFX are associated with transfusion independence at 24months. DFX is a safe, effective treatment for transfusion-dependent MDS that can lead to transfusion independence and haematological improvement in a subset of patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据